The blood-based proteomic test helps identify non-small cell lung cancer patients for epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Read MoreIf approved, the panel could be the first of its kind in the United States, and would serve as a companion diagnostic utilized to select patients for specific non-small cell lung cancer therapies.
Read MoreThe VeriStrat test is shown to have clinical utility in predicting overall survival of afatinib-treated patients with lung cancer.
Read More
The blood-based proteomic test for patients with advanced non-small cell lung cancer is now covered for another 3.8 million patients living in eastern United States.
Read More
The GeneStrat noninvasive, blood-based test is designed to provide accurate results in 72 hours for newly diagnosed non-small cell lung cancer patients.
Read More